---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-060529"
form_type: "8-K"
ticker: "TVRD"
cik: "0001346830"
company_name: "Tvardi Therapeutics, Inc."
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T02:00:46.073397+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cara Therapeutics Q1 2024 net loss $0.56/shr, revenue $2.1M; NP data by end 2Q24

## Summary
- Net loss $30.7M ($0.56/shr) vs $26.7M ($0.49) in Q1 2023; total revenue $2.1M down from $6.2M.
- Cash & marketable securities $69.8M at March 31, 2024, down from $100.8M at Dec 31, 2023; ops used $30.5M.
- KOURAGE 1 Part A topline NP results expected by end of Q2 2024; 214 patients enrolled, not powered for significance.
- KORSUVA injection net sales $1.8M in Q1 2024; TDAPA expired March 31, now reimbursed via ESRD bundle.
- Restructuring expenses $2.4M related to workforce reduction; R&D $22.0M vs $24.3M a year ago.

## SEC filing metadata
- accession: 0001104659-24-060529
- form_type: 8-K
- ticker: TVRD
- cik: 0001346830
- company_name: Tvardi Therapeutics, Inc.
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1346830/000110465924060529/0001104659-24-060529-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1346830/000110465924060529/tm2414193d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-060529
- JSON: https://secwatch.observer/filing/0001104659-24-060529.json
- Plain text: https://secwatch.observer/filing/0001104659-24-060529.txt

## Key facts
- Earnings Releases
  Tvardi Therapeutics, Inc. reported first quarter ended March 31, 2024 results: revenue $2.1 million, net income $30.7 million, EPS $(0.56) per basic and diluted share.
  - Period: first quarter ended March 31, 2024
  - Revenue: $2.1 million
  - Net income: $30.7 million
  - EPS: $(0.56) per basic and diluted share
  - Result: reported results
  source text: or $(0.56) per basic and diluted share, compared to net loss of $26.7 million, or ($0.49) per basic and diluted share, for the same period in 2023. Revenues: Total revenue was $2.1 million and $6.2 million for the three months ended March 31, 2024 and 2023, respectively. Revenue primarily consisted of: · $0.8 million and $2.8 million of collaborative revenue
  evidence_url: https://www.sec.gov/Archives/edgar/data/1346830/000110465924060529/0001104659-24-060529-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.